Vapotherm Inc

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.

Earnings data Q1 2023

Earnings data Q2 2023

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it was notified (the “Notice”) on March 15, 2023 by the New York Stock Exchange, Inc.

Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

Precigen

Penny stocks come with many risks, but with those risks come the potential for great rewards. While there is no guarantee which penny stocks will deliver those rewards, following the insiders is 1 way to find them.

3 Penny Stocks The Insiders Are Buying

Vapotherm (VAPO) delivered earnings and revenue surprises of 6.33% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates

Vapotherm, Inc. (NYSE:VAPO ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Mark Klausner - ICR Westwicke, IR Joe Army - President and CEO John Landry - Senior Vice President and CFO Conference Call Participants Zachary Day - Canaccord Genuity Sam Eiber - BTIG Operator Good afternoon. And welcome to Vapotherm's Fourth Quarter 2022 Financial Results Conference Call.

Vapotherm, Inc. (VAPO) Q4 2022 Earnings Call Transcript

EXETER, New Hampshire--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 Summary Total revenue for the fourth quarter of 2022 was $18.7 million Gross margin was 27.5% in the fourth quarter of 2022 Substantially completed move of manufacturing operations from New Hampshire to Mexico Fiscal Year 2022 Summary Total revenue for 2022 was $66.

Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vapotherm (VAPO) Q4 Earnings Expected to Decline

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.

Vapotherm Announces Closing of $23 Million Private Placement

Vapotherm Announces $23 Million Private Placement

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced preliminary unaudited fourth quarter and full year 2022 net results.

Vapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash Balance

Vapotherm has been struggling for years. The pandemic which appeared to be a blessing has not benefited the business at all; in fact, the contrary.

Vapotherm: Struggling For Air

Babcock & Wilcox Enterprises

Muscle Maker

NRX Pharmaceuticals

Tenaya Therapeutic

Venus Concept

Insiders and hedge funds are buying these penny stocks before December 2022. The post Penny Stocks To Buy: 6 Insider Picks Before December 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before December 2022

EXETER, N.H.--( BUSINESS WIRE )--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that, on November 21, 2022, the Company entered into Amendment No. 3 to its Loan and Security Agreement (the “Third Amendment,” with SLR Investment Corp. (“SLR”), as Collateral Agent, and the lenders party thereto.

Vapotherm Announces Amendment to Debt Agreement

Vapotherm, Inc. (NYSE:VAPO ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Joe Army - President & Chief Executive Officer John Landry - Senior Vice President & Chief Financial Officer Conference Call Participants Maggie Boeye - William Blair Jason Bednar - Piper Sandler Operator Good afternoon, ladies and gentlemen and welcome to Vapotherm's Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Mr.

Vapotherm, Inc. (VAPO) Q3 2022 Earnings Call Transcript

Vapotherm (VAPO) delivered earnings and revenue surprises of -16.88% and 19.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q3 Loss, Misses Revenue Estimates

Vapotherm Reports Third Quarter 2022 Financial Results

Vapotherm to Report Third Quarter 2022 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that, on September 30, 2022, the Company entered into an Amendment No. 2 to Loan and Security Agreement (the “Second Amendment,” together with the Loan and Secur

Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice

Vapotherm, Inc. (NYSE:VAPO ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Joe Army - President and Chief Executive Officer John Landry - Senior Vice President and Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Bill Plovanic - Canaccord Marie Thibault - BTIG Joseph Downing - Piper Sandler Operator Good afternoon, ladies and gentlemen. And welcome to the Vapotherm Second Quarter 2022 Financial Results Conference Call.

Vapotherm, Inc. (VAPO) CEO Joe Army on Q2 2022 Results - Earnings Call Transcript

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 via webcast. Vapotherm is sche

Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Vapotherm (VAPO) delivered earnings and revenue surprises of -7.69% and 32.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q2 Loss, Lags Revenue Estimates

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2022 financial results. Second Quarter 2022 Summary Total revenue for the second quarter of 2022 was $13.0 million, a decrease of 37.1% over the second quarter of 2021 Disposables revenue for the second quarter of 2022 was $7.9 million, a decrease of 38.2% over the second quarter of 2021 Worldwide installed base of Precision Flow systems increased by approximately 400 unit

Vapotherm Reports Second Quarter 2022 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022. Vapotherm's management team will hos

Vapotherm to Report Second Quarter 2022 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022. Vapotherm is scheduled to presen

Vapotherm to Participate in the William Blair 42nd Annual Growth Stock Conference

Vapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time.

Vapotherm: Out Of Air

Vapotherm, Inc. (NYSE:VAPO ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Joseph Army - CEO, President & Director John Landry - SVP, CFO & Treasurer Conference Call Participants Brandon Vazquez - William Blair & Company Sam Eiber - BTIG William Plovanic - Canaccord Genuity Operator Good afternoon, ladies and gentlemen, and welcome to the Vapotherm First Quarter 2022 Financial Results Conference Call. As a reminder, this call is being webcast live and recorded.

News for Vapotherm Inc Stock (VAPO)